In this week’s video, Dr. Brian GM Durie explains that the FDA will soon consider MRD-testing as a surrogate endpoint for both newly diagnosed and relapsed myeloma patients. 

BOTTOM LINE:
It is very likely that the FDA will approve both tests—NGS and NGF—within the next 1–2 years.

Have a question? Submit it to AskDrDurie@myeloma.org

IMF Chairman and Co-Founder Brian G.M. Durie, MD welcomes your questions about the latest myeloma treatments, research, controversies and quality of life issues. If you have a question you think might be of interest to the myeloma community, please send to askdrdurie@myeloma.org!

For questions of a specific personal nature, please call the IMF InfoLine coordinators at 800.452.2873 or email them at infoline@myeloma.org

Previous Post
Gene Editing, Regulating DNA Sequencing Tests, and How Your Body Gets Its Energy
Next Post
Can myeloma cells contaminate a patient’s stem cells that are harvested for transplant?

Give Where Most Needed

We use cookies on our website to support technical features that enhance your user experience.

We also use analytics & advertising services. To opt-out click for more information.